Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Drake, Alison L ^a   Roxby, Alison C ^a   Kiarie, James ^c   Richardson, Barbra A ^a,d   Wald, Anna ^a,d   John Stewart, Grace ^a,b   Farquhar, Carey ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NAIROBI   (Kenya)

^d USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; CREATININE; LAMIVUDINE; NEVIRAPINE; PLACEBO; VALACICLOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; VALINE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASTHMA; BACKACHE; BLEEDING; BLOOD SAMPLING; BRAIN DISEASE; BREAST ABSCESS; BREAST DISEASE; BREAST ENGORGEMENT; BREAST MILK; BRONCHITIS; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CERVICAL BLOOD; CHILD GROWTH; CHILD HOSPITALIZATION; COMMON COLD; CONGENITAL MALFORMATION; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEPRESSION; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DISEASE TRANSMISSION; DIZZINESS; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; DYSURIA; ECZEMA; ETHNIC GROUP; EXTERNAL OTITIS; FATIGUE; FEEDING BEHAVIOR; FEMALE; FEVER; FONTANEL; GASTROENTERITIS; GENITAL ULCER; GESTATIONAL AGE; GROWTH RETARDATION; HEART MURMUR; HEARTBURN; HEAT RASH; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTENSION; INFANT; IRRITABILITY; JAUNDICE; KENYAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALARIA; MASTALGIA; MASTITIS; MIXED INFECTION; MORTALITY; MOTHER TO CHILD TRANSMISSION; MOUTH ULCER; MYALGIA; MYCOSIS; NAUSEA; NEWBORN; NEWBORN SEPSIS; NIPPLE BLEEDING; NIPPLE CRACKING; NOSE CONGESTION; OTITIS MEDIA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHARYNGITIS; PNEUMONIA; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PROPHYLAXIS; PROTEINURIA; PRURITIC DERMATITIS; PUERPERIUM; RHINORRHEA; RICKETS; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SNEEZING; SORE THROAT; STILLBIRTH; SUNKEN FONTANELLE; TACHYCARDIA; THORAX PAIN; THRUSH; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX DISEASE; VAGINA DISCHARGE; VAGINAL PRURITUS; VOMITING; WASTING SYNDROME; WEIGHT REDUCTION; WHEEZING; YEAST INFECTION; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG TOXICITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOTHER; PREGNANCY; PRENATAL EXPOSURE; RANDOMIZED CONTROLLED TRIAL; TIME; VERTICAL TRANSMISSION;

HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 1;

ACYCLOVIR; ADULT; ANTI-HIV AGENTS; COINFECTION; DRUG TOXICITY; FEMALE; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MILK, HUMAN; MOTHERS; POSTPARTUM PERIOD; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TIME FACTORS; VALINE; YOUNG ADULT;

EID: 84859622513     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034635     Document Type: Article

References (24)

1. Hollier L, Wendel G, (2008) Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev.
2. Drake AL, John-Stewart GC, Wald A, Mbori-Ngacha DA, Bosire R, et al. (2007) Herpes Simplex Virus Type 2 and Risk of Intrapartum Human Immunodeficiency Virus Transmission. Obstet Gynecol 109: 403-409.
3. Mbopi-Keou FX, Gresenguet G, Mayaud P, Weiss HA, Gopal R, et al. (2000) Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 182: 1090-1096.
4. Hitti J, Watts DH, Burchett SK, Schacker T, Selke S, et al. (1997) Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. Am J Obstet Gynecol 177: 450-454.
5. John GC, Nduati RW, Mbori-Ngacha DA, Richardson BA, Panteleeff D, et al. (2001) Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 183: 206-212.
6. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, et al. (1993) Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 54: 595-605.
7. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, et al. (2002) Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 13: 12-21.
8. Pasternak B, Hviid A, (2010) Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 304: 859-866.
9. Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Brown Z, et al. (2004) Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol 70: 201-207.
10. Kimberlin DW, Whitley RJ, Wan W, Powell DA, Storch G, et al. (2011) Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med 365: 1284-1292.
11. Jacquemard F, Yamamoto M, Costa JM, Romand S, Jaqz-Aigrain E, et al. (2007) Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG 114: 1113-1121.
12. Sheffield JS, Fish DN, Hollier LM, Cadematori S, Nobles BJ, et al. (2002) Acyclovir concentrations in human breast milk after valaciclovir administration. Am J Obstet Gynecol 186: 100-102.
13. Brown SD, Bartlett MG, White CA, (2003) Pharmacokinetics of intravenous acyclovir, zidovudine, and acyclovir-zidovudine in pregnant rats. Antimicrob Agents Chemother 47: 991-996.
14. Drake AL, Roxby AC, Ongecha-Owuor F, Kiarie J, Wald A, et al. (2011) Valacyclovir Suppressive Therapy Reduces Plasma and Breast Milk HIV-1 RNA Levels During Pregnancy and Postpartum: A Randomized Trial. J Infect Dis 205: 366-375.
15. National Institute for Allergy and Infectious Disease (NIAID). Division of AIDS Toxicity Table for Grading the Severity of Adult and Pediatric Adverse Events, Publish Date December (2004) Available at http://www.ucdmc.ucdavis.edu/clinicaltrials/documents/DAIDS_AE_GradingTable_FinalDec2004.pdf. Accessed May 31, 2011.
16. Andersen PK, Gill RD, (1982) Cox's Regression Model for Counting Processes: A Large Sample Study. Ann Statist 10: 1100-1120.
17. World Heatlh Organization. (2006) WHO Child Growth Standards.
18. American Academy of Pediatrics, (2009) Herpes Simplex. Red Book 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL pp. 363-373.
19. Frenkel LM, Brown ZA, Bryson YJ, Corey L, Unadkat JD, et al. (1991) Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol 164: 569-576.
20. Kimberlin DF, Weller S, Whitley RJ, Andrews WW, Hauth JC, et al. (1998) Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Am J Obstet Gynecol 179: 846-851.
21. Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, et al. (2001) Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 108: 230-238.
22. American College of Obstetrics and Gynecologists (ACOG) (.2007) ACOG Practice Bulletin. Management of herpes in pregnancy. Clinical management guidelines for obstetrician-gynecologists. No. 82 June (2007) Management of herpes in pregnancy. Obstet Gynecol 109: 1489-1498.
23. Andrews WW, Kimberlin DF, Whitley R, Cliver S, Ramsey PS, et al. (2006) Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am J Obstet Gynecol 194: 774-781.
24. Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, et al. (2010) Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 375: 824-833.